Skip to main content

Medtronic plc. (MDT)

NYSE: MDT · Delayed Price · USD
129.00
-0.70 (-0.54%)
After-hours:Sep 17, 2021 7:24 PM EDT
129.70
-1.22 (-0.93%)
At close: Sep 17, 4:00 PM
Market Cap174.28B
Revenue (ttm)31.60B
Net Income (ttm)3.88B
Shares Out1.35B
EPS (ttm)2.86
PE Ratio45.37
Forward PE22.99
Dividend$2.37 (1.83%)
Ex-Dividend DateJun 24, 2021
Volume6,833,296
Open130.36
Previous Close130.92
Day's Range129.17 - 130.83
52-Week Range97.46 - 135.89
Beta0.81
AnalystsBuy
Price Target145.56 (+12.2%)
Est. Earnings DateNov 23, 2021

About MDT

Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; AF ablation products; insertable cardiac monitor systems; mechanical circulatory support; TYRX product...

IndustryHealth Care Equipment & Supplies
Founded1949
CEOGeoffrey Martha
Employees90,000
Stock ExchangeNYSE
Ticker SymbolMDT
Full Company Profile

Financial Performance

In 2021, Medtronic's revenue was $30.12 billion, an increase of 4.16% compared to the previous year's $28.91 billion. Earnings were $3.61 billion, a decrease of -24.70%.

Financial Statements

Analyst Forecast

According to 27 analysts, the average rating for Medtronic stock is "Buy." The 12-month stock price forecast is 145.56, which is an increase of 12.23% from the latest price.

Price Target
$145.56
(12.23% upside)
Analyst Consensus: Buy

News

2 Top Healthcare Stocks to Buy Right Now

Both of these stocks are healthcare leaders and they're trading at reasonable valuations.

Other symbols:UNH
18 hours ago - The Motley Fool

Medtronic's (MDT) Pilot Plan to Address SCA Care Disparities

Medtronic's (MDT) pilot program offers an advanced and scalable method to use real-world clinical data which enable quicker and appropriate care for patients at-risk of SCA.

2 days ago - Zacks Investment Research

U.S. Patent and Trademark Office Rejects Axonics' Challenge to Medtronic Patents

DUBLIN, Sept. 13, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has won three additional important victories in a dispute over its intellectu...

Other symbols:AXNX
4 days ago - PRNewsWire

Medtronic Collaboration with Mpirik to Address Disparities in Care Associated with Sudden Cardiac Arrest

DUBLIN, Sept. 13, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced a pilot program with Mpirik to address disparities in care associated with the ...

4 days ago - PRNewsWire

Medtronic's (MDT) Emprint Ablation System Study Data Positive

Medtronic's (MDT) Emprint Ablation Catheter Kit received Breakthrough Device Designation status from the FDA in April 2021 and is currently in development.

1 week ago - Zacks Investment Research

Medtronic Executives to Speak at Upcoming Investor Conferences

DUBLIN, Sept. 7, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it will participate virtually in the following upcoming investor conferences: 202...

1 week ago - PRNewsWire

Medtronic Announces NAVABLATE Study Results Released in Late-Breaking Podium Presentation at European Respiratory Soc...

Results Demonstrate Feasibility of Bronchoscopic Microwave Ablation for Certain Patients with Malignant Lung Nodules DUBLIN, Sept. 7, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in ...

1 week ago - PRNewsWire

Why Medtronic's Latest Quarterly Results Weren't as Good as They Might Seem

The healthcare giant posted strong growth. But there's more to the story.

1 week ago - The Motley Fool

7 Healthcare Stocks to Buy Before $3.5 Trillion Floods In

Covid-19 showed us how rapid advances in medicine and technology could create significant growth opportunities for healthcare stocks. The post 7 Healthcare Stocks to Buy Before $3.5 Trillion Floods In  ...

Other symbols:ABBVBAXJNJUNHVRTXXLV
2 weeks ago - InvestorPlace

Is This Medical-Device-Making Dividend Aristocrat a Buy?

Medtronic met analysts' consensus revenue estimate and exceeded earnings forecasts in the first quarter of its fiscal 2022.

2 weeks ago - The Motley Fool

Axonics: Buy at the High?

Axonics' stock price just hit its 52-week high, but its momentum means it's unlikely to last.

Other symbols:AXNX
2 weeks ago - The Motley Fool

BetterInvesting™ Magazine Selects Medtronic as "Growth" Stock and D.R. Horton as "Undervalued" For November 2021 Issue

TROY, Mich., Sept. 1, 2021 /PRNewswire/ -- The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Medtronic PLC (NYSE: MDT) as its "Stock to Study" and D.R.

Other symbols:DHI
2 weeks ago - PRNewsWire

Best Buy Continues to Impress; Medtronic Hits a New High

A look at stock market news.

Other symbols:BBY
2 weeks ago - The Motley Fool

Medtronic's (MDT) Micra TPS CED Study Outcome Favorable

Medtronic's (MDT) Micra TPS new study data supports the relationship of a lower risk of complications with leadless pacing.

2 weeks ago - Zacks Investment Research

Medtronic Shares Real-World Data For Micra Leadless Pacemaker

Medtronic Plc (NYSE: MDT) touted data demonstrating reductions in reinterventions and complications with its Micra pacemaker. Medtronic's Micra Coverage with Evidence Development (CED) study showed that...

3 weeks ago - Benzinga

6 Beautifully Boring Dividend Stocks

Instead of popular but volatile stocks, owning under-the-radar defensive gems will let you sleep at night.

Other symbols:COSTPEPPFERSGZTS
3 weeks ago - Kiplinger

Real-World Data Demonstrate Significant Reduction in Complications and Reinterventions with Medtronic Micra Leadless ...

Results Presented at ESC 2021 Show Micra TPS Compares Favorably to Traditional Pacemakers DUBLIN, Aug. 27, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today a...

3 weeks ago - PRNewsWire

Is There More Room For Growth In Medtronic Stock?

Medtronic recently reported its fiscal Q1 2022 results, which were better than our estimates. The company reported revenues of $8.0 billion, slightly above ours and the consensus estimate of $7.9 billion.

3 weeks ago - Forbes

Wednesday Afternoon Analyst Upgrades and Downgrades: Applied Materials, Best Buy, Intuit, Medtronic, Toll Brothers an...

The markets were higher across the board near midday, after a strong two-day rally opened the trading week.

Other symbols:AMATBBYINTUTOL
3 weeks ago - 24/7 Wall Street

Medtronic (MDT) Receives FDA Nod for Evolut FX TAVR System

Medtronic's (MDT) Evolut FX TAVR system offers hemodynamic and durability benefits of the Evolut platform with new product and procedure enhancements.

3 weeks ago - Zacks Investment Research

Why Medtronic Stock Popped Today

Medtronic "beat earnings" in Q1 -- and plans to keep on doing that all year long.

3 weeks ago - The Motley Fool

Medtronic Wins FDA Approval Of Next-Gen TAVR System For Aortic Stenosis

The FDA has approved Medtronic plc's (NYSE: MDT) Evolut FX TAVR system, a self-expanding transcatheter aortic valve replacement (TAVR) system.  The Evolut FX system incorporates the same supra-annular v...

3 weeks ago - Benzinga

The Delta variant will be ‘short lived,' Medtronic CEO says

Karen Parkhill, Medtronic CFO, joins Yahoo Finance Live to discuss the company's strong first-quarter financial results and break down how the company continues to advance their cardiac monitoring and A...

3 weeks ago - Yahoo Finance

Medtronic CEO on earnings, revenue beat and raised outlook

Medtronic chairman and CEO Geoffrey Martha joins CNBC's "Squawk on the Street" to discuss earnings and outlook.

3 weeks ago - CNBC Television

Medtronic's (MDT) Q1 Earnings Beat Estimates, Margins Up

Medtronic's (MDT) fiscal first-quarter results reflect a strong recovery from the impact of the COVID-19 pandemic on elective procedures that the company experienced in 2020.

3 weeks ago - Zacks Investment Research